Wed, Sep 17, 2014, 6:54 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • qdelfan qdelfan May 11, 2013 12:18 PM Flag

    Next week

    Bof A Merrill Lynch investor conference presentation on Tuesday evening next week, will update progress of the Vertex clinical trials, highlighting Phase 3 809/770 enrollment, and Phase 3 Kalydeco trials for an expanded monotherapy label, with expected timeline to NDA filings and approval next year. With Breakthrough drug designation, rapid FDA approval is likely,(it was a mere two month approval wait for Kalydeco aftrer it's inital NDA filing in early 2012). That means treatment for more than half the CF patients in the US alone starting next year, rather than the 4% currently being treated. That's a multibillion dollar revenue stream from CF alone....add in the future CF revenue from Europe, and and possible revenue from next generation CF corrrectors as well as VX 661 and VX 983, to further improve the potential treatment available for the "personalized" treatment of CF in the harder to treat CF patients e.g. heterozygote 508d CF population. And then add in the potential of the rest of pipeline ...... VX 135, 787 509 in next gernation hep C, influenza and anutoimmune diseases.

    It's no wonder mutual funds are supporting the stock at this level. In the meantime, standby for further announcements of lucrative partnerships with larger pharma interested in co-developing/marketing VX 787 and 509 with Vertex. Add in the over $1.2 Billion Vertex has in cash on hand, and the company is financially secure to pursue it's plans to develop it's pipeline.

 
VRTX
94.50+0.64(+0.68%)Sep 17 4:15 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.